Results 121 to 130 of about 110,785 (312)

Extent of Sinus Surgery Is Associated With Disease Control in Biologic Treated Type 2 Dominant CRS

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background A greater benefit of biologics is observed after surgery in Type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). However, the extent of surgery remains undefined in many studies. This study evaluated the extent of surgery on disease control in patients receiving biologics for refractory Type 2 dominant CRSwNP.
Nicholas J. Campion   +11 more
wiley   +1 more source

Massive eosinophil infiltration. (×100). [PDF]

open access: yes, 2012
Massive eosinophil infiltration. (×100).
Wei Li (7081)   +6 more
core   +1 more source

Leptin May Promote Eosinophilic CRSwNP Progression by Enhancing Eosinophil Chemotaxis and Angiogenesis Under a Type 2 Inflammatory Milieu

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyp (CRSwNP) is a heterogeneous Type 2 inflammatory disease characterized by enhanced eosinophilic infiltration. Both innate and adaptive immunity are involved in the onset and progression of CRSwNP.
Yuki Sonoda   +4 more
wiley   +1 more source

Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies

open access: yesBiomolecules
Eosinophilic granulomatosis with polyangiitis (EGPA) is a necrotizing vasculitis characterized by extravascular granulomas and eosinophilia in both blood and tissues.
Mayu Shiomi   +5 more
doaj   +1 more source

Th2 cytokines and asthma — The role of interleukin-5 in allergic eosinophilic disease

open access: yesRespiratory Research, 2001
Interleukin-5 is produced by a number of cell types, and is responsible for the maturation and release of eosinophils in the bone marrow. In humans, interleukin-5 is a very selective cytokine as a result of the restricted expression of the interleukin-5 ...
Chapman Richard W   +4 more
doaj   +1 more source

Clinical Significance of Interleukin 33 (IL-33) in Patients with Eosinophilic Pneumonia

open access: yesAllergology International, 2013
Background: Interleukin 33 (IL-33) works as a functional mediator in allergic disease by enhancing the activity of eosinophils and inducing expression of T helper 2 (Th2)-associated cytokines.
Naoko Mato   +8 more
doaj   +1 more source

Antiviral roles of eosinophils in asthma and respiratory viral infection

open access: yesFrontiers in Allergy
Eosinophils are immune cells that are crucial for the pathogenesis of allergic diseases, such as asthma. These cells play multifunctional roles in various situations, including infection.
Hisashi Sasaki   +5 more
doaj   +1 more source

Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps—Are We Comparing Apples With Oranges?

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
Key Points In recent years, several biologics targeting Type 2 inflammation have been developed for treating chronic rhinosinusitis with nasal polyps (CRSwNP). These have been studied in registrational randomized controlled trials (RCTs), which vary in their patient populations, trial design, endpoints, geography, timing, or data‐handling processes ...
Marjolein Cornet   +10 more
wiley   +1 more source

Eosinophilic myenteric ganglionitis is associated with functional intestinal obstruction [PDF]

open access: yes, 2003
The diagnostic features and clinical course of three children (aged 1 month to 15 years) with severe functional intestinal obstruction and inflammation of the colonic lamina propria and myenteric plexus are described.
Smith, VV   +3 more
core  

Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) in Chinese patients often exhibits a mixed Type 1/2/3 inflammatory phenotype (63%), potentially impacting the efficacy of biologics targeting Type 2 inflammation. This prespecified subgroup analysis of WAYPOINT (NCT04851964) evaluated the efficacy and safety of tezepelumab in Chinese
Li Hu   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy